Michael Palfreyman
Non-Executive Director Thalia Therapeutics
Dr Michael Palfreyman has more than four decades of successful drug discovery and development experience with two major pharmaceutical companies and several biotechnology companies and is currently the co-founder, director and senior advisor at AlNivo Therapeutics. Previous roles include SVP of Scriptgen (Anadys) Pharmaceuticals, which was sold to Roche in 2011 for USD$230 million, co-founder and CSO at Amorsa Therapeutics, Inc., developing novel treatments for depression and pain, where he oversaw a successful US$180 million exit, and co-founder and COO of Adelia Therapeutics sold to Cybin (now Helos Pharma) with their compounds now in advanced clinical trials. Dr Palfreyman is a co-inventor on 56 issued US and European patents, multiple pending patents, and has co-authored over 150 scientific articles and book chapters.
Seminars
- Understand what investors and pharmaceutical partners look for
- Learn how to find and build relationships with investors/partners interested in your field
- Gain insights into the key conferences, partnering forums and networking platforms that are shaping investment and dealmaking
